F
François Dabis
Researcher at French Institute of Health and Medical Research
Publications - 13
Citations - 3541
François Dabis is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Hazard ratio & Population. The author has an hindex of 8, co-authored 13 publications receiving 3420 citations. Previous affiliations of François Dabis include University of Bordeaux.
Papers
More filters
Journal ArticleDOI
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.
Matthias Egger,Margaret T May,Geneviève Chêne,Andrew N. Phillips,Bruno Ledergerber,François Dabis,Dominique Costagliola,Antonella d'Arminio Monforte,Frank de Wolf,Peter Reiss,Jens D Lundgren,Amy C. Justice,Schlomo Staszewski,Catherine Leport,Robert S. Hogg,Caroline A. Sabin,M. John Gill,Bernd Salzberger,Jonathan A C Sterne +18 more
TL;DR: The CD4 cell count at initiation was the dominant prognostic factor in patients starting HAART, and should be taken into account in future treatment guidelines.
Journal ArticleDOI
Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries.
Paula Braitstein,Mwg Brinkhof,François Dabis,Mauro Schechter,Andrew Boulle,Paolo G. Miotti,Robin Wood,Christian Laurent,Eduardo Sprinz,Catherine Seyler,David R. Bangsberg,Eric Balestre,Jonathan A C Sterne,Margaret T May,Matthias Egger +14 more
TL;DR: Patients starting HAART in resource-poor settings have increased mortality rates in the first months on therapy, compared with those in developed countries, and timely diagnosis and assessment of treatment eligibility, coupled with free provision of HAART might reduce this excess mortality.
Journal ArticleDOI
HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population.
Charlotte Lewden,Geneviève Chêne,Philippe Morlat,François Raffi,Michel Dupon,Pierre Dellamonica,Jean-Luc Pellegrin,Christine Katlama,François Dabis,Catherine Leport +9 more
TL;DR: In this paper, the authors compared mortality rates in combination antiretroviral therapy (cART)-treated HIV-infected adults with mortality in the general population according to the level of CD4 cell count reached and the duration of exposure to cART.
Journal ArticleDOI
Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries
Martin W. G. Brinkhof,François Dabis,Landon Myer,David R. Bangsberg,Andrew Boulle,Denis Nash,Mauro Schechter,Christian Laurent,Olivia Keiser,Margaret T May,Eduardo Sprinz,Matthias Egger,Xavier Anglaret +12 more
TL;DR: Early patient losses were increasingly common when programmes were scaled up and were associated with a fee for service and advanced immunodeficiency at baseline, and measures to maximize ART programme retention are required in resource-poor countries.
Journal ArticleDOI
The case for an HIV cure and how to get there
Mark Dybul,Timothy Attoye,Solange Baptiste,Peter Cherutich,François Dabis,Steven G. Deeks,Carl W. Dieffenbach,Brian P. Doehle,Maureen M Goodenow,Adam Jiang,Dominic Kemps,Sharon R Lewin,Murray Lumpkin,Lauren Mathae,Joseph M. McCune,Thumbi Ndung'u,Moses Supercharger Nsubuga,Holly L. Peay,Pottage John C,Mitchell Warren,Izukanji Sikazwe +20 more
TL;DR: This work proposes steps to plan for an HIV cure now, including defining a target product profile and establishing the HIV Cure Africa Acceleration Partnership (HCAAP), a multidisciplinary public-private partnership that will catalyse and promote HIV cure research through diverse stakeholder engagement.